Immunohistochemistry in the workup of bladder biopsies: Frequency, variation and utility of use at an academic center.

[1]  M. Brunelli,et al.  Evolving concepts and use of immunohistochemical biomarkers in flat non-neoplastic urothelial lesions: WHO 2016 classification update with diagnostic algorithm , 2018, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[2]  L. True,et al.  Flat Urothelial Lesions With Atypia: Interobserver Concordance and Added Value of Immunohistochemical Profiling , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  S. Williamson,et al.  CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia. , 2018, Archives of pathology & laboratory medicine.

[4]  M. Abolhasani,et al.  Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67 , 2016, Medical journal of the Islamic Republic of Iran.

[5]  R. Mak,et al.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Delahunt,et al.  Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology: Report From the International Society of Urological Pathology Consensus Conference , 2014, The American journal of surgical pathology.

[7]  D. Grignon,et al.  Best Practices Recommendations in the Application of Immunohistochemistry in the Bladder Lesions: Report From the International Society of Urologic Pathology Consensus Conference , 2014, The American journal of surgical pathology.

[8]  F. Brimo,et al.  The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu. , 2014, Annals of diagnostic pathology.

[9]  J. McKenney,et al.  Utility of a Triple Antibody Cocktail Intraurothelial Neoplasm-3 (IUN-3-CK20/CD44s/p53) and &agr;-Methylacyl-CoA Racemase (AMACR) in the Distinction of Urothelial Carcinoma In Situ (CIS) and Reactive Urothelial Atypia , 2013, The American journal of surgical pathology.

[10]  A. Gown,et al.  Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases. , 2013, Human pathology.

[11]  A. Niemierko,et al.  Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.

[12]  C. Busch,et al.  Diagnosis of intraurothelial neoplasia. Interobserver variation and the value of individual histopathologic attributes. , 2011, Analytical and quantitative cytology and histology.

[13]  R. Dhir,et al.  Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies , 2009, Diagnostic pathology.

[14]  M. Amin,et al.  Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  Y. Lotan,et al.  Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. , 2007, European urology.

[16]  G. Botti,et al.  [A useful panel in proliferative urothelial lesions: an analysis of cytokeratin 20, p53, CD44 and Ki-67 antigens]. , 2007, Pathologica.

[17]  A. Zietman,et al.  Bladder-sparing approaches to invasive disease , 2006, World Journal of Urology.

[18]  S. Shariat,et al.  Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. , 2003, Urology.

[19]  M. Solé,et al.  Immunohistochemical Expression of CK20, p53, and Ki-67 as Objective Markers of Urothelial Dysplasia , 2003, Modern Pathology.

[20]  G. Herrera,et al.  p53 Protein and Ki-67 Overexpression in Urothelial Dysplasia of Bladder , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[21]  J. McKenney,et al.  Discriminatory Immunohistochemical Staining of Urothelial Carcinoma in Situ and Non-neoplastic Urothelium: An Analysis of Cytokeratin 20, p53, and CD44 Antigens , 2001, The American journal of surgical pathology.

[22]  T. H. van der Kwast,et al.  Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation , 2001, Virchows Archiv.

[23]  J. Cheville,et al.  Survival of patients with carcinoma in situ of the urinary bladder , 1999, Cancer.

[24]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[25]  G. Farrow,et al.  The plight of the patient with carcinoma in situ of the bladder. , 1970, The Journal of urology.